Results Of Biomarker Analysis From Phase Ii Trial Of Nivolumab In Refractory Biliary Tract Cancer.

Elaine Tan,Dae Won Kim,Junmin Zhou,Michael J. Schell,Vincent Chung,Olatunji B. Alese,Richard D. Kim

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 0|浏览11

暂无评分

摘要

338Background: Our previous phase II study demonstrated that nivolumab provides modest but durable clinical efficacy in patients (pts) with refractory biliary tract cancer (BTC), suggesting the sig...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要